ALNY vs MAMO · P/E 76, rev $1.29B vs rev $71.8M
Alnylam Pharmaceuticals Inc (ALNY) versus Massimo Group Common Stock (MAMO) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Massimo Group Common Stock (MAMO) is a recreational vehicles company listed on US.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported MAMO revenue for 2025-12-31 was $71.8M. Net income was $1.5M. Revenue was up 3680.4% from 2024-12-31 to 2025-12-31. MAMO currently screens at market cap $115.9M.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. MAMO currently screens at market cap $115.9M.
Not investment advice. Open the ALNY and MAMO stock pages for the full models.
Not investment advice.